The leading source for credible citizen reporting

Report Your News
Take the tour...

Ineffective monotherapies dominating high-burden malarious countries

Source: Sify News
Lagos : Nigeria | 23 days ago  
Views: 1
A new study has shown that owing to high price of artemisinin combination therapy (ACT), the most effective medicines for treating malaria, ineffective monotherapies are dominating high-burden malarious countries. Dr. Kathryn O'Connell said that majority of malaria endemic countries changed...
  • Print
  • Share:
  • Share
  • Digg
  • Reddit
  • Facebook
  • Stumbleupon

Related Allvoices Contributions

News Stories
 
  • News Source: Reuters | 23 days ago
    Nearly a million people die from malaria each year because they cannot afford the most effective treatment and instead often buy old drugs to which the malaria parasite has become resistant, researchers said on Monday. Artemisinin combination...
  • News Source: Sify News | 23 days ago
    A new study has shown that owing to high price of artemisinin combination therapy (ACT), the most effective medicines for treating malaria, ineffective monotherapies are dominating high-burden malarious countries. Dr. Kathryn O'Connell said that...
Blogs
 >
  • Blog Source: www.scienceblog.com
    Ineffective monotherapies common in high-burden malarious countries. (November 2, 2009; Nairobi) ACTwatch, a research project led by PSI, in collaboration with the London School of Hygiene and Tropical Medicine, released evidence today ... to ban
  • Blog Source: p-phosphorus.info
    Ineffective monotherapies common in high-burden malarious countries. Written by EurekAlert! - Medicine and Health on November 2, 2009 – 5:00 am -. (Powell Tate) ACTwatch, a research project led by PSI, in collaboration with the London School of ...
Images
 >
 
Report Your News Got a similar story?
Add it to the network!

Or add related content to this report

Cell phones Cell phones use report code: @4535643

Most Popular Reports

Contributions

Help and Accounts


Use of this site is governed by our Terms of Use Agreement and Privacy Policy.

© Allvoices, Inc 2008-2009. All rights reserved.